These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31915153)

  • 1. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
    Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
    Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A; Solis-Herrera C; Daniele G; Eldor R; Fiorentino TV; Tripathy D; Xiong J; Perez Z; Norton L; Abdul-Ghani MA; DeFronzo RA
    J Clin Invest; 2014 Feb; 124(2):509-14. PubMed ID: 24463448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
    Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
    Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C; Kerr-Conte J; Gmyr V; Queniat G; Moerman E; Thévenet J; Beaucamps C; Delalleau N; Popescu I; Malaisse WJ; Sener A; Deprez B; Abderrahmani A; Staels B; Pattou F
    Nat Med; 2015 May; 21(5):512-7. PubMed ID: 25894829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
    Alatrach M; Agyin C; Solis-Herrera C; Lavryneko O; Adams J; Gastaldelli A; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes Care; 2022 Jun; 45(6):1372-1380. PubMed ID: 35235659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
    Merovci A; Mari A; Solis-Herrera C; Xiong J; Daniele G; Chavez-Velazquez A; Tripathy D; Urban McCarthy S; Abdul-Ghani M; DeFronzo RA
    J Clin Endocrinol Metab; 2015 May; 100(5):1927-32. PubMed ID: 25710563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
    Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects.
    Chen X; Tripathy D; Chilton R; Hansis-Diarte A; Salehi M; Solis-Herrera C; Cersosimo E; DeFronzo RA
    Diabetes; 2024 Jun; 73(6):896-902. PubMed ID: 38512770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
    Herring RA; Shojaee-Moradie F; Garesse R; Stevenage M; Jackson N; Fielding BA; Mendis A; Johnsen S; Umpleby AM; Davies M; Russell-Jones DL
    Diabetes Care; 2020 Sep; 43(9):2128-2136. PubMed ID: 32641376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.
    Tanday N; Irwin N; Flatt PR; Moffett RC
    Biochem Pharmacol; 2020 Jul; 177():114009. PubMed ID: 32360307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes.
    Boeder SC; Gregory JM; Giovannetti ER; Pettus JH
    Diabetes; 2022 Mar; 71(3):511-519. PubMed ID: 34857545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
    Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; van Hall G; Holst JJ; Knop FK; Vilsbøll T
    Diabetes; 2020 Dec; 69(12):2619-2629. PubMed ID: 33004472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
    Cersosimo E; Alatrach M; Solis-Herrera C; Baskoy G; Adams J; Hansis-Diarte A; Gastaldelli A; Chavez A; Triplitt C; DeFronzo RA
    J Clin Endocrinol Metab; 2023 Dec; 109(1):161-170. PubMed ID: 37481263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do sodium-glucose co-transporter-2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?
    Kuhre RE; Deacon CF; Wewer Albrechtsen NJ; Holst JJ
    Diabetes Obes Metab; 2021 Sep; 23(9):2009-2019. PubMed ID: 33961344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.
    Daniele G; Solis-Herrera C; Dardano A; Mari A; Tura A; Giusti L; Kurumthodathu JJ; Campi B; Saba A; Bianchi AM; Tregnaghi C; Egidi MF; Abdul-Ghani M; DeFronzo R; Del Prato S
    Diabetologia; 2020 Nov; 63(11):2423-2433. PubMed ID: 32827269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.